MANISH DHAWAN, MD

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Established patient office or other outpatient visit, 40-54 minutes

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Biopsy and aspiration of bone marrow sample for diagnosis

New patient office or other outpatient visit, 45-59 minutes

Administration of chemotherapy into vein, 1 hour or less

Established patient office or other outpatient visit, 30-39 minutes

Administration of prolonged chemotherapy into vein

New patient office or other outpatient visit, 30-44 minutes

Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Drawing of blood for a medical problem

Established patient office or other outpatient visit, 20-29 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein, 1 hour or less

Established patient office or other outpatient visit, 10-19 minutes

Injection, pembrolizumab, 1 mg

Administration of additional new drug or substance into vein using push technique

Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and

Infusion into a vein for hydration, 31-60 minutes

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of chemotherapy into vein, each additional hour

Irrigation of implanted venous access drug delivery device

Injection, denosumab, 1 mg

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Application of on-body injector for under skin injection

Injection of additional new drug or substance into vein

Injection of drug or substance under skin or into muscle

Injection, epoetin alfa, (for non-esrd use), 1000 units

Injection, zoledronic acid, 1 mg

Injection, methylprednisolone sodium succinate, up to 40 mg

Injection, leucovorin calcium, per 50 mg

Infusion, normal saline solution , 1000 cc

Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg

Injection, fluorouracil, 500 mg

Injection, ferric carboxymaltose, 1 mg

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Injection, palonosetron hcl, 25 mcg

Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

Injection, diphenhydramine hcl, up to 50 mg

Injection, fosaprepitant, 1 mg

Injection, ondansetron hydrochloride, per 1 mg

Injection, dexamethasone sodium phosphate, 1 mg